Related Experiment Video
Updated: Jul 16, 2026
07:31
Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
Published on: May 15, 2020
Dynamic staging and risk factor scoring for gestational trophoblastic disease
1Trophoblast Center, Department of Gynecology, Yale University School of Medicine, New Haven, Connecticut, USA. ernest.kohorn@yale.edu
Summary
A dynamic staging and risk factor scoring system for gestational trophoblastic disease is proposed. This system allows for real-time updates, improving patient classification and management of this complex condition.
Area of Science:
- Gynecology
- Oncology
- Medical Informatics
Background:
- Current FIGO staging for gestational trophoblastic disease (GTD) has limitations.
- The 2002 FIGO modification integrated anatomic staging with WHO risk factor scoring but has drawbacks.
- Hydatidiform mole is not classified, and staging timing is not mandated.
Purpose of the Study:
- To propose a dynamic staging and risk factor scoring system for GTD.
- To enhance the precision of GTD classification and patient monitoring.
- To address limitations of the current FIGO system, including the classification of hydatidiform mole and invasive mole.
Main Methods:
- Leveraging modern computer technology for dynamic data updates.
- Integrating FIGO anatomic staging with WHO risk factor scoring.
- Developing a system allowing for changes in stage and risk score over time.
Main Results:
- A dynamic system permits continuous reassessment of GTD patient status.
- Allows for the inclusion of more clinical detail than the current FIGO system.
- Potentially resolves the issue of including invasive mole in classification.
Conclusions:
- A dynamic staging and risk factor scoring system offers a more precise approach to GTD management.
- This system addresses the static nature of current classifications.
- It provides a flexible framework for evolving disease status and classification challenges.
Related Concept Videos
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...